# OnCo record neuroendocrine (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/neuroendocrine/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "neuroendocrine" ;
  schema:name "Neuroendocrine tumours"@en ;
  schema:alternateName "Gastrointestinal Neuroendocrine Tumors"@en, "Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)"@en ;
  schema:description "A family of usually slow-growing tumours that start in hormone-producing cells of the gut, pancreas and lungs. They pioneered the idea of using the same molecule to see a tumour on a scan and then to treat it with radiation."@en ;
  schema:url <https://onco.cc/cancers/neuroendocrine/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Neuroendocrine_tumor> ;
  owl:sameAs <http://www.wikidata.org/entity/Q1981276> ;
  schema:citation <https://en.wikipedia.org/wiki/Neuroendocrine_tumor> ;
  onco:tag "endocrine", "spike" ;
  onco:related <https://onco.cc/pairings/sstr-pet-to-prrt/>, <https://onco.cc/pairings/prrt-then-alpha-net/>, <https://onco.cc/roadmaps/radiopharma-roadmap/>, <https://onco.cc/pairings/beta-then-alpha/> ;
  onco:technologies <https://onco.cc/technologies/radioligand-therapy/>, <https://onco.cc/technologies/targeted-alpha-therapy/>, <https://onco.cc/technologies/pet/>, <https://onco.cc/technologies/sstr-pet/>, <https://onco.cc/technologies/prrt/>, <https://onco.cc/technologies/pet-ct/>, <https://onco.cc/technologies/tace/>, <https://onco.cc/technologies/radioembolisation-tare/>, <https://onco.cc/technologies/thermal-ablation/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/histopathology-ihc/> ;
  onco:targets <https://onco.cc/targets/sstr2/>, <https://onco.cc/targets/vegf/>, <https://onco.cc/targets/met/>, <https://onco.cc/targets/akt/>, <https://onco.cc/targets/menin/>, <https://onco.cc/targets/hif2a/>, <https://onco.cc/targets/dll3/> ;
  onco:drugs <https://onco.cc/drugs/i131-mibg/>, <https://onco.cc/drugs/telotristat-ethyl/> ;
  onco:companies <https://onco.cc/companies/crinetics-pharmaceuticals/>, <https://onco.cc/companies/molecular-partners/>, <https://onco.cc/companies/sinotau-pharmaceutical/>, <https://onco.cc/companies/vyriad/>, <https://onco.cc/companies/novartis/>, <https://onco.cc/companies/ipsen/>, <https://onco.cc/companies/itm/>, <https://onco.cc/companies/orano-med/>, <https://onco.cc/companies/radiomedix/>, <https://onco.cc/companies/sanofi/>, <https://onco.cc/companies/rayzebio/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/exelixis/>, <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/alliance-oncology/>, <https://onco.cc/companies/ecog-acrin/> ;
  onco:institutions <https://onco.cc/institutions/mskcc/>, <https://onco.cc/institutions/uke-hamburg/>, <https://onco.cc/institutions/heidelberg-nct/>, <https://onco.cc/institutions/royal-marsden/> ;
  onco:terms <https://onco.cc/terms/net-grade-ki67/>, <https://onco.cc/terms/chromogranin-a/>, <https://onco.cc/terms/carcinoid-syndrome/>, <https://onco.cc/terms/men1-hereditary-net/>, <https://onco.cc/terms/theranostics/>, <https://onco.cc/terms/alpha-vs-beta/>, <https://onco.cc/terms/dosimetry/> ;
  onco:trials <https://onco.cc/trials/nct06943755/>, <https://onco.cc/trials/netter-1/>, <https://onco.cc/trials/nct05459844/>, <https://onco.cc/trials/nct06398444/>, <https://onco.cc/trials/nct07544654/>, <https://onco.cc/trials/nct07087054/>, <https://onco.cc/trials/nct04919226/> ;
  onco:people <https://onco.cc/people/steve-jobs/> ;
  onco:journals <https://onco.cc/journals/endocrine-related-cancer/> ;
  onco:pipeline <https://onco.cc/drugs/ryz101/>, <https://onco.cc/drugs/pm8002/>, <https://onco.cc/drugs/zg006/>, <https://onco.cc/drugs/zanzalintinib/>, <https://onco.cc/drugs/peluntamig/>, <https://onco.cc/drugs/itm-11/>, <https://onco.cc/trials/compete/>, <https://onco.cc/drugs/alphamedix/>, <https://onco.cc/trials/alphamedix-02/>, <https://onco.cc/trials/action-1/>, <https://onco.cc/technologies/prrt/>, <https://onco.cc/technologies/sstr-pet/>, <https://onco.cc/drugs/cabozantinib/>, <https://onco.cc/ideas/idea-net-dosimetry-prrt/>, <https://onco.cc/ideas/idea-net-antagonist-ligands/>, <https://onco.cc/pairings/prrt-then-alpha-net/>, <https://onco.cc/drugs/tarlatamab/>, <https://onco.cc/targets/dll3/> ;
  onco:standardOfCare <https://onco.cc/drugs/lutathera/>, <https://onco.cc/drugs/ryz101/>, <https://onco.cc/technologies/sstr-pet/>, <https://onco.cc/terms/net-grade-ki67/>, <https://onco.cc/terms/chromogranin-a/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/terms/men1-hereditary-net/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/drugs/octreotide-lanreotide/>, <https://onco.cc/trials/promid/>, <https://onco.cc/trials/clarinet/>, <https://onco.cc/drugs/lutathera/>, <https://onco.cc/technologies/prrt/>, <https://onco.cc/drugs/lutathera/>, <https://onco.cc/drugs/itm-11/>, <https://onco.cc/trials/compete/>, <https://onco.cc/drugs/everolimus/>, <https://onco.cc/trials/radiant-3-4/>, <https://onco.cc/drugs/sunitinib/>, <https://onco.cc/drugs/cabozantinib/>, <https://onco.cc/trials/cabinet/>, <https://onco.cc/drugs/capecitabine-temozolomide/>, <https://onco.cc/technologies/tace/>, <https://onco.cc/technologies/radioembolisation-tare/>, <https://onco.cc/technologies/thermal-ablation/>, <https://onco.cc/drugs/octreotide-lanreotide/>, <https://onco.cc/terms/carcinoid-syndrome/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/tarlatamab/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/ryz101/>, <https://onco.cc/trials/action-1/>, <https://onco.cc/drugs/alphamedix/>, <https://onco.cc/pairings/prrt-then-alpha-net/>, <https://onco.cc/drugs/belzutifan/>, <https://onco.cc/terms/men1-hereditary-net/> .